- Home
- FLGC vs NXTC Comparison
FLGC vs NXTC Comparison
Compare FLGC & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLGC
- NXTC
- Stock Information
- Founded
- FLGC 2019
- NXTC 2015
- Country
- FLGC United States
- NXTC United States
- Employees
- FLGC N/A
- NXTC N/A
- Industry
- FLGC Biotechnology: Pharmaceutical Preparations
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- FLGC Health Care
- NXTC Health Care
- Exchange
- FLGC Nasdaq
- NXTC Nasdaq
- Market Cap
- FLGC 15.9M
- NXTC 13.0M
- IPO Year
- FLGC 2021
- NXTC 2019
- Fundamental
- Price
- FLGC $27.89
- NXTC $5.67
- Analyst Decision
- FLGC Strong Buy
- NXTC Strong Buy
- Analyst Count
- FLGC 1
- NXTC 2
- Target Price
- FLGC $156.00
- NXTC $25.50
- AVG Volume (30 Days)
- FLGC 10.2K
- NXTC 14.1K
- Earning Date
- FLGC 11-12-2025
- NXTC 11-06-2025
- Dividend Yield
- FLGC N/A
- NXTC N/A
- EPS Growth
- FLGC N/A
- NXTC N/A
- EPS
- FLGC N/A
- NXTC N/A
- Revenue
- FLGC $52,373,000.00
- NXTC N/A
- Revenue This Year
- FLGC N/A
- NXTC N/A
- Revenue Next Year
- FLGC $10.22
- NXTC N/A
- P/E Ratio
- FLGC N/A
- NXTC N/A
- Revenue Growth
- FLGC N/A
- NXTC N/A
- 52 Week Low
- FLGC $15.15
- NXTC $2.69
- 52 Week High
- FLGC $82.29
- NXTC $19.20
- Technical
- Relative Strength Index (RSI)
- FLGC 55.63
- NXTC 64.35
- Support Level
- FLGC N/A
- NXTC $5.19
- Resistance Level
- FLGC $24.95
- NXTC $5.15
- Average True Range (ATR)
- FLGC 1.32
- NXTC 0.27
- MACD
- FLGC -0.30
- NXTC 0.07
- Stochastic Oscillator
- FLGC 99.96
- NXTC 80.63
About FLGC Flora Growth Corp.
Flora Growth Corp is a multi-national cannabis company that manufactures and distributes consumer packaged goods, cultivates and distributes medicinal cannabis, and distributes pharmaceutical products. Its reportable segments are: the commercial and wholesale segment (FGH and Cosechemos subsidiaries) and the house of brands segment (JustCBD, Vessel, and Kasa Wholefoods Company subsidiaries). Geographically, the company generates revenue from the United States, Germany, Australia, and the United Kingdom. It generates revenue as a distributor of pharmaceutical goods, and a manufacturer and reseller of a range of cannabis-based and complementary products.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.